Casdin Capital Reduces Stake in BioLife Solutions to 9.7% Following Series of Share Dispositions

On May 22, 2026, Casdin Capital, LLC, along with affiliated reporting persons including Casdin Partners Master Fund, L.P. and Eli Casdin, filed an amendment to their Schedule 13D regarding BioLife Solutions, Inc. (BLFS). The filing reveals that the group now beneficially owns 4,757,165 shares of Common Stock, representing a 9.7% ownership stake in the company. This follows a series of recent dispositions in May 2026, including the sale of 300,000 shares at $22.65 on May 19, 250,000 shares at $23.70 on May 20, and 650,000 shares at $23.70 on May 21. Despite these sales, the Reporting Persons maintain a significant position for investment purposes and have engaged in discussions with management and the Board of Directors regarding strategies to maximize shareholder value. The funds for the initial acquisitions originated from the working capital of the Master Fund. The reporting persons reserve the right to further adjust their holdings or propose corporate changes as market conditions evolve.